Cardioprotection with beta-blockers: Myths, facts and Pascal's wager

Journal of Internal Medicine

Volumn 266, Issue 3, 2009, Pages 232-241

  Messerli, F H ^a,b   Bangalore, S ^b   Yao, S S ^b   Steinberg, J S ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Angina; Atrial fibrillation; Coronary artery disease; Heart failure; Hypertension; New onset diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

DEPRESSION; DIABETES MELLITUS; DIZZINESS; FATIGUE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PROTECTION; HEART REINFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEXUAL DYSFUNCTION; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; ATRIAL FIBRILLATION; HEART FAILURE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 68949131187     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02140.x     Document Type: Review

References (53)

1. Kennedy John F 1962). Commencement address. Speech presented at Yale University, New Haven, CT, USA.
2. Orwell S, Angus I. The Collected Essays, Journalism and Letters of George Orwell, Vol. 3, 1968.
3. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985 27 : 335 71.
4. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA, 1998 279 : 1903 7.
5. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 366 : 1545 53 (Review).
6. Wiysonge CS, Bradley H, Mayosi BM et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007 CD002003.
7. JNC 6. National High Blood Pressure Education Program. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997 157 : 2413 46.
8. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the swedish trial in old patients with hypertension (STOP-hypertension). Lancet 1991 338 : 1281 5.
9. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986 293 : 1145 51.
10. Kaboli PJ, Shivapour DM, Henderson MS, Barnett MJ, Ishani A, Carter BL. Patient and provider perceptions of hypertension treatment: do they agree? J Clin Hypertens 2007 9 : 416 23.
11. Fleisher LA, Beckman JA, Brown KA et al. J Am Coll Cardiol 2007 50 : 1707 32.
12. Fleisher LA, Beckman JA, Brown KA et al. Circulation 2006 113 : 2662 74.
13. Fleisher LA, Beckman JA, Brown KA et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. Circulation 2006 113 : 2662 74.
14. Kannel WB, Kannel C, Paffenbarger Jr. RS, Cupples LA. Heart rate and cardiovascular mortality: the framingham study. Am Heart J 1987 113 : 1489 94.
15. Palatini P, Thijs L, Staessen JA et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002 162 : 2313 21.
16. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005 26 : 967 74.
17. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986 57 : 43F 9F.
18. Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM. High heart rate: a cardiovascular risk factor? Eur Heart J 2006 27 : 2387 93.
19. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008 52 : 1482 9.
20. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007 370 : 591 603.
21. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 113 : 1213 25.
22. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 112 : e154 235.
23. Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. βeta-blockers for primary prevention of heart failure in patients with hypertension: insights from a meta-analysis. J Am Coll Cardiol 2008 52 : 1062 72.
24. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med 2000 342 : 905 12.
25. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007 100 : 1254 62.
26. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007 369 : 201 7.
27. Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004 43 : 963 9.
28. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999 33 : 1130 4.
29. Davey Smith G, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med 2005 142 : 313 22.
30. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007 25 : 1311 7.
31. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007 50 : 467 73.
32. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005 95 : 29 35.
33. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008 117 : 2706 15.
34. Galve E, Rius T, Ballester R et al. Intravenous amiodarone in the treatment of recent-onset atrial fibrillation. Results of a randomized, controlled study. J Am Coll Cardiol 1996 27 : 1079.
35. Peuhkurinen K, Niemelä M, Ylitalo A, Linnaluoto M, Lilja M, Juvonen J. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol 2000 85 : 462.
36. Gallagher MM, Guo XH, Poloniecki JD, Guan Yap Y, Ward D, Camm AJ. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol 2001 38 : 1498.
37. Dittrich HC, Erickson JS, Schneiderman T, Blacky AR, Savides T, Nicod PH. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989 63 : 193.
38. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006 48 : e149.
39. Kühlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000 36 : 139.
40. Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001 135 : 1061 73 (Review).
41. Echahidi N, Pibarot P, O'Hara G, Mathieu P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008 51 : 793 801 (Review).
42. Steinberg JS. Atrial Fibrillation after Cardiac Surgery. New York : Springer, 1999.
43. Mathew JP, Fontes ML, Tudor IC et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004 291 : 1720 9.
44. Gibbons RJ, Abrams J, Chatterjee K et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. 2002 Available at: http://www.acc.org/qualityandscience/clinical/statements.htm
45. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006 27 : 1341.
46. Warren SG, Brewer DL, Orgain ES. Long-term propranolol therapy for angina pectoris. Am J Cardiol 1976 37 : 420.
47. Jackson G, Harry JD, Robinson C, Kitson D, Jewitt DE. Comparison of atenolol with propranolol in the treatment of angina pectoris with special reference to once daily administration of atenolol. Br Heart J 1978 40 : 998.
48. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative3 Group. Lancet 1986 2 : 57.
49. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999 318 : 1730.
50. Pascal Blaise (composed in 1600s, first published in 1800s) Pensees, section 343; translated & reprinted by Penguin and many others.
51. POISE Study Group, Devereaux PJ, Yang H et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008 371 : 1839 47.
52. Chen ZM, Pan HC, Chen YP et al. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005 366 : 1622 32.
53. Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet 2008 372 : 1962 76.